Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia

Pfizer will no longer develop and commercialize its hemophilia B gene therapy Beqvez across all of its global markets, according to multiple media reports Thursday.

In a statement to Nikkei Asia, the pharma said that the decision was due to “the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.” Beqvez, a one-time treatment, was approved by the FDA in April 2024 and was given a list price of $3.5 million per dose at launch.